<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TENEX  - guanfacine hydrochloride tablet </strong><br>Promius Pharma, LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="_8a6d4f34-9bd3-8ddb-06c3-a8ec7c778a98"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with α<span class="Sub">2</span>-adrenoceptor agonist properties in tablet form for oral administration.</p>
<p> The chemical name of Tenex (guanfacine hydrochloride) is N-amidino- 2-(2,6-dichlorophenyl) acetamide hydrochloride and its molecular weight is 282.56. Its structural formula is:<br></p>
<p></p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=886e050c-dd22-4f35-ac3b-243f091125c3&amp;name=structure.jpg"></p>
<p></p>
<p>Guanfacine hydrochloride is a white to off-white powder; sparingly soluble in water and alcohol and slightly soluble in acetone. The tablets contain the following inactive ingredients:</p>
<p> 1 mg—FD&amp;C Red 40 aluminum lake, lactose, microcrystalline cellulose, povidone, stearic acid.</p>
<p> 2 mg—D&amp;C Yellow 10 aluminum lake, lactose, microcrystalline cellulose, povidone, stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clinical_pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tenex (guanfacine hydrochloride) is an orally active antihypertensive
                     agent whose principal mechanism of action appears to be stimulation of central
                        α<span class="Sub">2</span>-adrenergic receptors. By stimulating these
                     receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor
                     center to the heart and blood vessels. This results in a decrease in peripheral
                     <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and a reduction in heart rate. </p>
<p>The dose-response relationship for blood pressure and adverse effects
                     of guanfacine given once a day as monotherapy has been evaluated in patients
                     with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. In this study patients were randomized to
                     placebo or to 0.5 mg, 1 mg, 2 mg, 3 mg, or 5 mg of Tenex. Results are shown in
                     the following table. A useful effect was not observed overall until doses of 2
                     mg were reached, although responses in white patients were seen at 1 mg; 24
                     hour effectiveness of 1 mg to 3 mg doses was documented using 24 hour
                     ambulatory monitoring. While the 5 mg dose added an increment of effectiveness,
                     it caused an unacceptable increase in adverse reactions.</p>
<a name="Table_1"></a><table width="75%">
<caption><span>Mean Changes (mm Hg) from Baseline in Seated Systolic and Diastolic
                        Blood Pressure for Patients Completing 4 to 8 Weeks of Treatment with
                        Guanfacine Monotherapy</span></caption>
<col align="left" valign="bottom" width="30%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<thead><tr class="First Last">
<th align="left">Mean Change S/D<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Seated</th>
<th align="center">n = (range)</th>
<th align="center">Placebo</th>
<th align="center">0.5 mg</th>
<th align="center">1 mg</th>
<th align="center">2 mg</th>
<th align="center">3 mg</th>
<th align="center">5 mg</th>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>S/D = Systolic/diastolic
                                 blood pressure</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">White Patients</td>
<td align="center">11–30</td>
<td align="center">-1/-5</td>
<td align="center">-6/-8</td>
<td align="center">-8/-9</td>
<td align="center">-12/-11</td>
<td align="center">-15/-12</td>
<td align="center">-18/-16</td>
</tr>
<tr class="Last">
<td align="left">Black Patients</td>
<td align="center">8–28</td>
<td align="center">-3/-5</td>
<td align="center">0/-2</td>
<td align="center">-3/-5</td>
<td align="center">-7/-7</td>
<td align="center">-8/-9</td>
<td align="center">-19/-15</td>
</tr>
</tbody>
</table>
<br><br><p>Controlled clinical trials in patients with mild to moderate
                     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> who were receiving a thiazide-type diuretic have defined the
                     dose-response relationship for blood pressure response and adverse reactions of
                     guanfacine given at bedtime and have shown that the blood pressure response to
                     guanfacine can persist for 24 hours after a single dose. In the 12-week
                     placebo-controlled dose-response study, patients were randomized to placebo or
                     to doses of 0.5, 1, 2, and 3 mg of guanfacine, in addition to 25 mg
                     chlorthalidone, each given at bedtime. The observed mean changes from baseline,
                     tabulated below, indicate the similarity of response for placebo and the 0.5 mg
                     dose. Doses of 1, 2, and 3 mg resulted in decreased blood pressure in the
                     sitting position with no real differences among the three doses. In the
                     standing position, there was some increase in response with dose.</p>
<a name="Table_2"></a><table width="75%">
<caption><span>Mean Decreases (mm Hg) in Seated and Standing Blood Pressure for
                        Patients Treated with Guanfacine in Combination with Chlorthalidone</span></caption>
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<col align="center" valign="bottom" width="14%">
<thead><tr class="First Last">
<th align="left">Mean Change</th>
<th align="center">n =</th>
<th align="center">Placebo<br>63</th>
<th align="center">0.5 mg<br>63</th>
<th align="center">1 mg<br>64</th>
<th align="center">2 mg<br>58</th>
<th align="center">3 mg<br>59</th>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>S/D = Systolic/diastolic blood
                              pressure</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">SD<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> Seated</td>
<td align="center"><br></td>
<td align="center">-5/-7</td>
<td align="center">-5/-6</td>
<td align="center">-14/-13</td>
<td align="center">-12/-13</td>
<td align="center">-16/-13</td>
</tr>
<tr class="Last">
<td align="left">SD Standing</td>
<td align="center"><br></td>
<td align="center">-3/-5</td>
<td align="center">-5/-4</td>
<td align="center">-11/-9</td>
<td align="center">-9/-10</td>
<td align="center">-15/-12</td>
</tr>
</tbody>
</table>
<br><p>While most of the effectiveness of guanfacine in combination (and as
                     monotherapy in white patients) was present at 1 mg, adverse reactions at this
                     dose were not clearly distinguishable from those associated with placebo.
                     Adverse reactions were clearly present at 2 and 3 mg (see <span class="Bold"><a href="#Adverse_reactions">ADVERSE REACTIONS</a></span>).</p>
<p>In a second 12-week placebo-controlled study of 1, 2 or 3 mg of Tenex
                     (guanfacine hydrochloride) administered with 25 mg of chlorthalidone once
                     daily, a significant decrease in blood pressure was maintained for a full 24
                     hours after dosing. While there was no significant difference between the 12
                     and 24 hour blood pressure readings, the <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> at 24 hours was
                     numerically smaller, suggesting possible escape of blood pressure in some
                     patients and the need for individualization of therapy.</p>
<p>In a double-blind, randomized trial, either guanfacine or clonidine was
                     given at recommended doses with 25 mg chlorthalidone for 24 weeks and then
                     abruptly discontinued. Results showed equal degrees of blood pressure reduction
                     with the two drugs and there was no tendency for blood pressures to increase
                     despite maintenance of the same daily dose of the two drugs. Signs and symptoms
                     of rebound phenomena were infrequent upon discontinuation of either drug.
                     Abrupt withdrawal of clonidine produced a rapid return of diastolic and
                     especially systolic blood pressure to approximately pretreatment levels, with
                     occasional values significantly greater than baseline, whereas guanfacine
                     withdrawal produced a more gradual increase to pretreatment levels, but also
                     with occasional values significantly greater than baseline.</p>
<div class="Section" data-sectionCode="43681-6">
<a name="Pharmcodynamics"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Hemodynamic studies in man showed that the decrease in blood
                           pressure observed after single-dose or long-term oral treatment with
                           guanfacine was accompanied by a significant decrease in peripheral
                           resistance and a slight reduction in heart rate (5 beats/min). Cardiac
                           output under conditions of rest or exercise was not altered by
                           guanfacine.</p>
<p>Tenex (guanfacine hydrochloride) lowered elevated plasma renin
                           activity and plasma catecholamine levels in hypertensive patients, but
                           this does not correlate with individual blood-pressure responses.</p>
<p>Growth hormone secretion was stimulated with single oral doses of
                           2 and 4 mg of guanfacine. Long-term use of Tenex had no effect on
                           growth hormone levels.</p>
<p>Guanfacine had no effect on plasma aldosterone. A slight but
                           insignificant decrease in plasma volume occurred after one month of
                           guanfacine therapy. There were no changes in mean body weight or
                           electrolytes.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Pharmacokinetics"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Relative to an intravenous dose of 3 mg, the absolute oral
                           bioavailability of guanfacine is about 80%. Peak plasma concentrations
                           occur from 1 to 4 hours with an average of 2.6 hours after single oral
                           doses or at steady state.</p>
<p>The area under the concentration-time curve (AUC) increases
                           linearly with the dose.</p>
<p>In individuals with normal renal function, the average
                           elimination half-life is approximately 17 hr (range 10 - 30 hr). Younger
                           patients tend to have shorter elimination half-lives (13 - 14 hr) while
                           older patients tend to have half-lives at the upper end of the range.
                           Steady state blood levels were attained within 4 days in most subjects.</p>
<p>In individuals with normal renal function, guanfacine and its
                           metabolites are excreted primarily in the urine. Approximately 50% (40 -
                           75%) of the dose is eliminated in the urine as unchanged drug; the
                           remainder is eliminated mostly as conjugates of metabolites produced by
                           oxidative metabolism of the aromatic ring.</p>
<p>The guanfacine-to-creatinine clearance ratio is greater than 1.0,
                           which would suggest that tubular secretion of drug occurs.</p>
<p>The drug is approximately 70% bound to plasma proteins,
                           independent of drug concentration.</p>
<p>The whole body volume of distribution is high (a mean of 6.3
                           L/kg), which suggests a high distribution of drug to the tissues.</p>
<p>The clearance of guanfacine in patients with varying degrees of
                           <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is reduced, but plasma levels of drug are only
                           slightly increased compared to patients with normal renal function. When
                           prescribing for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the low end of the dosing
                           range should be used. Patients on dialysis also can be given usual doses
                           of guanfacine hydrochloride as the drug is poorly dialyzed.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_b7a626cf-9abc-8c50-5ec7-c8c7b7a3b092"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Tenex (guanfacine hydrochloride) is indicated in the
                     management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Tenex may be given alone or in combination
                     with other antihypertensive agents, especially thiazide-type
                  diuretics.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_37b1c350-d8af-4f2c-4934-4b6ea3d7597f"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Tenex is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to
                     guanfacine hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Precautions"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<span class="Bold">General</span><p class="First">Like other antihypertensive agents, Tenex (guanfacine hydrochloride)
                     should be used with caution in patients with severe coronary insufficiency,
                     recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cerebrovascular disease, or chronic renal or
                     <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
<br><span class="Bold">Sedation</span><p>Tenex, like other orally active central
                     α<span class="Sub">2</span>-adrenergic agonists, causes sedation or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>,
                     especially when beginning therapy. These symptoms are dose-related (see
                     <span class="Bold"><a href="#Adverse_reactions">ADVERSE REACTIONS</a></span>). When Tenex is
                     used with other centrally active depressants (such as phenothiazines,
                     barbiturates, or benzodiazepines), the potential for additive sedative effects
                     should be considered.</p>
<br><span class="Bold">Rebound</span><p>Abrupt cessation of therapy with orally active central
                        α<span class="Sub">2</span>-adrenergic agonists may be associated with increases
                     (from depressed on-therapy levels) in plasma and urinary catecholamines,
                     symptoms of "<span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>" and, less commonly, increases in blood
                     pressure to levels significantly greater than those prior to
                  therapy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Information_for_patients"></a><a name="section-6"></a><p></p>
<h1>Information for Patients</h1>
<p class="First">Patients who receive Tenex should be advised to exercise caution when
                     operating dangerous machinery or driving motor vehicles until it is determined
                     that they do not become drowsy or dizzy from the medication. Patients should be
                     warned that their tolerance for alcohol and other CNS depressants may be
                     diminished. Patients should be advised not to discontinue therapy
                  abruptly.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Laboratory_tests"></a><a name="section-7"></a><p></p>
<h1>Laboratory Tests</h1>
<p class="First">In clinical trials, no clinically relevant laboratory test
                     abnormalities were identified as causally related to drug during short-term
                     treatment with Tenex (guanfancine hydrochloride).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_interactions"></a><a name="section-8"></a><p></p>
<h1>Drug Interactions</h1>
<p class="First">The potential for increased sedation when Tenex is given with other
                     CNS-depressant drugs should be appreciated.</p>
<p>The administration of guanfacine concomitantly with a known microsomal
                     enzyme inducer (phenobarbital or phenytoin) to two patients with renal
                     impairment reportedly resulted in significant reductions in elimination
                     half-life and plasma concentration. In such cases, therefore, more frequent
                     dosing may be required to achieve or maintain the desired hypotensive response.
                     Further, if guanfacine is to be discontinued in such patients, careful tapering
                     of the dosage may be necessary in order to avoid rebound phenomena (see
                     <span class="Bold"><a href="#Rebound">Rebound</a></span> above).</p>
<span class="Bold">Anticoagulants</span><p>Ten patients who were stabilized on oral anticoagulants were given
                     guanfacine, 1 - 2 mg/day, for 4 weeks. No changes were observed in the degree
                     of anticoagulation.</p>
<p>In several well-controlled studies, guanfacine was administered
                     together with diuretics with no drug interactions reported. In the long-term
                     safety studies, Tenex was given concomitantly with many drugs without evidence
                     of any interactions. The principal drugs given (number of patients in
                     parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103),
                     coronary vasodilators (52), oral hypoglycemics (45), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>
                     preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24),
                     oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers
                     (10).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="_557838f8-1b9e-0d4b-e7fa-12f521e7a29b"></a><a name="section-9"></a><p></p>
<h1>Drug/Laboratory Test Interactions</h1>
<p class="First">No laboratory test abnormalities related to the use of Tenex
                     (guanfacine hydrochloride) have been identified.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Carcinogenesis"></a><a name="section-10"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, Impairment of Fertility</h1>
<p class="First">No carcinogenic effect was observed in studies of 78 weeks in mice at
                     doses more than 150 times the maximum recommended human dose and 102 weeks in
                     rats at doses more than 100 times the maximum recommended human dose. In a
                     variety of test models, guanfacine was not mutagenic.</p>
<p>No adverse effects were observed in fertility studies in male and
                     female rats.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="<span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>"></a><a name="section-10.1"></a><p></p>
<h2>Pregnancy Category B</h2>
<p class="First">Administration of guanfacine to rats at 70 times the maximum
                           recommended human dose and to rabbits at 20 times the maximum recommended
                           human dose resulted in no evidence of harm to the fetus. Higher doses
                           (100 and 200 times the maximum recommended human dose in rabbits and rats
                           respectively) were associated with reduced fetal survival and maternal
                           toxicity. Rat experiments have shown that guanfacine crosses the
                           placenta.</p>
<p>There are, however, no adequate and well-controlled studies in
                           pregnant women. Because animal reproduction studies are not always
                           predictive of human response, this drug should be used during pregnancy
                           only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Pregnancy"></a><a name="section-11"></a><p></p>
<div class="Section" data-sectionCode="34079-4">
<a name="Labor_and_delivery"></a><a name="section-11.1"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Tenex (guanfacine hydrochloride) is not recommended in the
                           treatment of acute <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> associated with <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>.
                           There is no information available on the effects of guanfacine on the
                           course of labor and delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="_32267252-508a-428a-ed4b-8c3d3873ffdc"></a><a name="section-11.2"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether Tenex (guanfacine hydrochloride) is
                           excreted in human milk. Because many drugs are excreted in human milk,
                           caution should be exercised when Tenex is administered to a nursing
                           woman. Experiments with rats have shown that guanfacine is excreted in
                           the milk.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Use_in_specific_populations"></a><a name="section-12"></a><p></p>
<div class="Section" data-sectionCode="34081-0">
<a name="Pediatric_use"></a><a name="section-12.1"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children under 12 years of age have not been demonstrated. Therefore, the use of Tenex in this age group is not recommended. There have been spontaneous postmarketing reports of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> and aggressive behavioral changes in pediatric patients with attention-deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder (<span class="product-label-link" type="condition" conceptid="4228617" conceptname="Add">ADHD</span>) receiving Tenex. The reported cases were from a single center. All patients had medical or family risk factors for bipolar disorder. All patients recovered upon discontinuation of guanfacine HCl. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have been reported in pediatric patients receiving Tenex for treatment of attention-deficit <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> disorder.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Geriatric_use"></a><a name="section-12.2"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Tenex did not include sufficient numbers of
                           subjects aged 65 and over to determine whether they responded differently
                           from younger subjects. Other reported clinical experience has not
                           identified differences in responses between the elderly and younger
                           patients.</p>
<p>In general, dose selection for an elderly patient should be
                           cautious, usually starting at the low end of the dosing range, reflecting
                           the greater frequency of decreased hepatic, renal or cardiac function,
                           and of concomitant disease or other drug therapy (see <span class="Bold"><a href="#Pharmacokinetics">CLINICAL PHARMACOLOGY:
                              Pharmacokinetics</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_reactions"></a><a name="section-13"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions noted with Tenex (guanfacine hydrochloride) are
                     similar to those of other drugs of the central
                     α<span class="Sub">2</span>-adrenoreceptor agonist class: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, sedation
                     (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.
                     While the reactions are common, most are mild and tend to disappear on
                     continued dosing.</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> with <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">exfoliation</span> has been reported in a few cases; although
                     clear cause and effect relationships to Tenex could not be established, should
                     a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occur, Tenex should be discontinued and the patient monitored
                     appropriately.</p>
<p>In the dose-response monotherapy study described under <span class="Bold"><a href="#Clinical_pharmacology">CLINICAL PHARMACOLOGY</a></span>, the frequency of the
                     most commonly observed adverse reactions showed a dose relationship from 0.5 to
                     3 mg as follows:</p>
<a name="Table_3"></a><table width="75%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th align="left">Adverse<br>Reaction</th>
<th align="center">Placebo<br>n=59</th>
<th align="center">0.5 mg<br>n=60</th>
<th align="center">1 mg<br>n=61</th>
<th align="center">2 mg<br>n=60</th>
<th align="center">3 mg<br>n=59</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">0%</td>
<td align="center">10%</td>
<td align="center">10%</td>
<td align="center">42%</td>
<td align="center">54%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">8%</td>
<td align="center">5%</td>
<td align="center">10%</td>
<td align="center">13%</td>
<td align="center">39%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">3%</td>
<td align="center">7%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">8%</td>
<td align="center">12%</td>
<td align="center">2%</td>
<td align="center">8%</td>
<td align="center">15%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">8%</td>
<td align="center">13%</td>
<td align="center">7%</td>
<td align="center">5%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">0%</td>
<td align="center">7%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">0%</td>
<td align="center">2%</td>
<td align="center">0%</td>
<td align="center">5%</td>
<td align="center">15%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">5%</td>
<td align="center">8%</td>
<td align="center">10%</td>
</tr>
</tbody>
</table>
<p>The percent of patients who dropped out because of adverse reactions
                     are shown below for each dosage group.</p>
<a name="Table_4"></a><table width="75%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th align="left"><br></th>
<th align="center">Placebo</th>
<th align="center">0.5 mg</th>
<th align="center">1 mg</th>
<th align="center">2 mg</th>
<th align="center">3 mg</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="left">Percent dropouts</td>
<td align="center">0%</td>
<td align="center">2.0%</td>
<td align="center">5.0%</td>
<td align="center">13%</td>
<td align="center">32%</td>
</tr></tbody>
</table>
<p>The most common reasons for dropouts among patients who received
                     guanfacine were <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and
                     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p>In the 12-week, placebo-controlled, dose-response study of guanfacine
                     administered with 25 mg chlorthalidone at bedtime, the frequency of the most
                     commonly observed adverse reactions showed a clear dose relationship from 0.5
                     to 3 mg as follows:</p>
<a name="Table_5"></a><table width="75%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th align="left">Adverse<br>Reaction</th>
<th align="center">Placebo<br>n=73</th>
<th align="center">0.5 mg<br>n=72</th>
<th align="center">1 mg<br>n=72</th>
<th align="center">2 mg<br>n=72</th>
<th align="center">3 mg<br>n=72</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">5 (7%)</td>
<td align="center">4 (5%)</td>
<td align="center">6 (8%)</td>
<td align="center">8 (11%)</td>
<td align="center">20 (28%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">1 (1%)</td>
<td align="center">3 (4%)</td>
<td align="center">0 (0%)</td>
<td align="center">1 (1%)</td>
<td align="center">10 (14%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">0 (0%)</td>
<td align="center">2 (3%)</td>
<td align="center">0 (0%)</td>
<td align="center">2 (2%)</td>
<td align="center">7 (10%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">2 (2%)</td>
<td align="center">1 (1%)</td>
<td align="center">3 (4%)</td>
<td align="center">6 (8%)</td>
<td align="center">3 (4%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">3 (4%)</td>
<td align="center">4 (3%)</td>
<td align="center">3 (4%)</td>
<td align="center">1 (1%)</td>
<td align="center">2 (2%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td align="center">1 (1%)</td>
<td align="center">1 (0%)</td>
<td align="center">0 (0%)</td>
<td align="center">1 (1%)</td>
<td align="center">3 (4%)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">0 (0%)</td>
<td align="center">0 (0%)</td>
<td align="center">0 (0%)</td>
<td align="center">1 (1%)</td>
<td align="center">1 (1%)</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">3 (3%)</td>
<td align="center">2 (3%)</td>
<td align="center">2 (3%)</td>
<td align="center">5 (6%)</td>
<td align="center">3 (4%)</td>
</tr>
</tbody>
</table>
<p>There were 41 premature terminations because of adverse reactions in
                     this study. The percent of patients who dropped out and the dose at which the
                     dropout occurred were as follows:</p>
<a name="Table_6"></a><table width="75%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th align="left">Dose</th>
<th align="center">Placebo</th>
<th align="center">0.5 mg</th>
<th align="center">1 mg</th>
<th align="center">2 mg</th>
<th align="center">3 mg</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="left">Percent dropouts</td>
<td align="center">6.9%</td>
<td align="center">4.2%</td>
<td align="center">3.2%</td>
<td align="center">6.9%</td>
<td align="center">8.3%</td>
</tr></tbody>
</table>
<p>Reasons for dropouts among patients who received guanfacine were:
                     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>,
                     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and
                     <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.</p>
<p>In a second 12-week placebo-controlled combination therapy study in
                     which the dose could be adjusted upward to 3 mg per day in 1-mg increments at
                     3-week intervals, i.e., a setting more similar to ordinary clinical use, the
                     most commonly recorded reactions were: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, 47%; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, 16%;
                     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, 12%; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, 10%; <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, 6%; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, 6%; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, 4%; and
                     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, 4%.</p>
<p>Reasons for dropouts among patients who received guanfacine were:
                     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>,
                     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
<p>In the clonidine/guanfacine comparison described in <span class="Bold"><a href="#Clinical_pharmacology">CLINICAL PHARMACOLOGY</a></span>, the most common adverse
                     reactions noted were as follows:</p>
<a name="Table_7"></a><table width="75%">
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left">Adverse<br>Reactions</th>
<th align="center">Guanfacine<br>(n=279)</th>
<th align="center">Clonidine<br>(n=278)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">30%</td>
<td align="center">37%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">21%</td>
<td align="center">35%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">11%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">10%</td>
<td align="center">5%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">9%</td>
<td align="center">8%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">4%</td>
<td align="center">4%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">4%</td>
<td align="center">3%</td>
</tr>
</tbody>
</table>
<p>Adverse reactions occurring in 3% or less of patients in the three
                     controlled trials of Tenex (guanfacine hydrochloride) with a diuretic were:</p>
<p> Cardiovascular- <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal pain</span></p>
<p> Gastrointestinal- <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>,
                     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p> CNS- <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, libido decrease</p>
<p> ENT disorders- <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p> <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>- <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, vision disturbance</p>
<p> Musculoskeletal- <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span></p>
<p> Respiratory- <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p> Dermatologic- <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></p>
<p> Urogenital- <span class="product-label-link" type="condition" conceptid="4276801" conceptname="Disorder of testis">testicular disorder</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span></p>
<p> Other- <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span></p>
<p>Adverse reaction reports tend to decrease over time. In an open-label
                     trial of one year's duration, 580 hypertensive subjects were given guanfacine,
                     titrated to achieve goal blood pressure, alone (51%), with diuretic (38%), with
                     beta blocker (3%), with diuretic plus beta blocker (6%), or with diuretic plus
                     vasodilator (2%). The mean daily dose of guanfacine reached was 4.7 mg.</p>
<a name="Table_8"></a><table width="75%">
<col align="left" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="33%">
<thead>
<tr class="First">
<th align="left">Adverse<br>Reaction</th>
<th align="center">Incidence of adverse reactions at any time during the study</th>
<th align="center">Incidence of adverse reactions at end of one year</th>
</tr>
<tr class="Last">
<th align="left"><br></th>
<th align="center">n = 580</th>
<th align="center">n = 580</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="center">60%</td>
<td align="center">15%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td align="center">33%</td>
<td align="center">6%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">15%</td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">14%</td>
<td align="center">3%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td align="center">5%</td>
<td align="center">1%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">4%</td>
<td align="center">0.2%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">5%</td>
<td align="center">0%</td>
</tr>
</tbody>
</table>
<p>There were 52 (8.9%) dropouts due to adverse effects in this 1-year
                     trial. The causes were: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (n = 20), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (n = 12), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (n
                     = 7), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (n = 3), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (n = 3), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (n = 2),
                     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (n = 1), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (n = 1), <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span> (n = 1), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (n = 1), and
                     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (n = 1).</p>
<span class="Bold">Postmarketing Experience</span><p>An open-label postmarketing study involving 21,718 patients was
                     conducted to assess the safety of  Tenex (guanfacine hydrochloride) 1 mg/day
                     given at bedtime for 28 days. Tenex was administered with or without other
                     antihypertensive agents. Adverse events reported in the postmarketing study at
                     an incidence greater than 1% included <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>,
                     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The most commonly reported adverse events in this
                     study were the same as those observed in controlled clinical trials.</p>
<p>Less frequent, possibly Tenex-related events observed in the
                     postmarketing study and/or reported spontaneously include:</p>
<p>BODY AS A WHOLE <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p>
<p>CARDIOVASCULAR <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p>CENTRAL NERVOUS SYSTEM <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">EYE DISORDERS</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></p>
<p>GASTROINTESTINAL SYSTEM <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>,
                     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span></p>
<p>LIVER AND BILLIARY SYSTEM <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span></p>
<p>MUSCULO-SKELETAL SYSTEM <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p>PSYCHIATRIC <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>,
                     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></p>
<p>RREPRODUCTIVE SYSTEM, Male- <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span></p>
<p>RESPIRATORY SYSTEM <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p>SKIN AND APPENDAGES <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,
                     <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p>SPECIAL SENSES alterations in taste</p>
<p>URINARY SYSTEM <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></p>
<p>Rare, serious disorders with no definitive cause and effect
                     relationship to Tenex have been reported spontaneously and/or in the
                     postmarketing study. These events include <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, cardiac
                     <span class="product-label-link" type="condition" conceptid="4226399" conceptname="Fibrillation">fibrillation</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>,
                     and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="_ef83a4d8-0a9e-1afb-9938-b1021d64c1e6"></a><a name="section-14"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">No reported abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> has been associated with the
                     administration of Tenex (guanfacine hdyrochloride).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="_d6d268db-3624-2fda-0610-4f1d660a3c61"></a><a name="section-15"></a><p></p>
<h1>OVERDOSAGE</h1>
<span class="Bold">Signs and Symptoms</span><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been observed
                     following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with guanfacine.</p>
<p>A 25-year-old female intentionally ingested 60 mg. She presented with
                     severe <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> of 45 beats/minute. Gastric lavage was
                     performed and an infusion of isoproterenol (0.8 mg in 12 hours) was
                     administered. She recovered quickly and without sequelae.</p>
<p>A 28-year-old female who ingested 30 - 40 mg developed only <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>,
                     was treated with activated charcoal and a cathartic, was monitored for 24
                     hours, and was discharged in good health.</p>
<p>A 2-year-old male weighing 12 kg who ingested up to 4 mg of guanfacine
                     developed <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. Gastric lavage (followed by activated charcoal and sorbitol
                     slurry via NG tube) removed some tablet fragments within 2 hours after
                     ingestion, and vital signs were normal.</p>
<p>During 24-hour observation in ICU, systolic pressure was 58 and heart
                     rate 70 at 16 hours post-ingestion. No intervention was required, and child
                     was discharged fully recovered the next day.</p>
<span class="Bold">Treatment of
                        Overdosage</span><p>Gastric lavage and supportive therapy as appropriate.
                     Guanfacine is not dialyzable in clinically significant amounts
                  (2.4%).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_ee905776-1ccf-e901-5f7a-120ffb44b63b"></a><a name="section-16"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended initial dose of Tenex (guanfacine hydrochloride) when
                     given alone or in combination with another antihypertensive drug is 1 mg daily
                     given at bedtime to minimize <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. If after 3 to 4 weeks of therapy 1 mg
                     does not give a satisfactory result, a dose of 2 mg may be given, although most
                     of the effect of Tenex is seen at 1 mg (see <span class="Bold"><a href="#Clinical_pharmacology">CLINICAL PHARMACOLOGY</a></span>). Higher daily doses have been used, but
                     adverse reactions increase significantly with doses above 3 mg/day.</p>
<p>The frequency of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> is low, but it can occur. When
                     rebound occurs, it does so after 2 - 4 days, which is delayed compared with
                     clonidine hydrochloride. This is consistent with the longer half-life of
                     guanfacine. In most cases, after abrupt withdrawal of guanfacine, blood
                     pressure returns to pretreatment levels slowly (within 2 - 4 days) without ill
                     effects.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="_fb5b763d-a357-88eb-71c2-242a1b4fe51d"></a><a name="section-17"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"> Tenex<span class="Sup">®</span> (guanfacine hydrochloride) Tablets are available in the following dosing strengths (expressed in equivalent amounts of guanfacine): </p>
<p> 1 mg—light pink, diamond-shaped tablet embossed with a 1 and engraved RP on one side and engraved TENEX on the other side in bottles of 100 (NDC 67857-705-01) and 500 (NDC 67857-705-05). </p>
<p> 2 mg—yellow, diamond-shaped tablet, one side engraved TENEX, other side engraved 2 with RP below it in bottles of 100 (NDC 67857-706-01). </p>
<p><span class="Bold">Store at controlled temperature, between 20ଌ and 25°C (68°F and 77°F).</span></p>
<p><span class="Bold">Dispense in a tight, light-resistant container.</span></p>
<p>Distributed by:<br>Promius Pharma, LLC<br>Bridgewater, NJ 08807</p>
<p>Manufactured by:<br>PATHEON, Puerto Rico, Inc.<br>Manati, Puerto Rico 00674, USA</p>
<p>Revised: May 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_1a377031-c76d-5eca-1e99-11a9caf823bb"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First">NDC-67857-706-01 100 Tablets</p>
<p>TENEX®</p>
<p>(Guanfancine HCL)</p>
<p>equivalent to<br>2 mg guanfancine</p>
<p>Rx only</p>
<p>PROMIUS PHARMA</p>
<p><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=886e050c-dd22-4f35-ac3b-243f091125c3&amp;name=label.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_7ac74f0d-466b-ed83-3350-57ee6b8b351d"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First">NDC-67857-705-05 500 Tablets</p>
<p>TENEX®</p>
<p>(Guanfancine HCL)</p>
<p>equivalent to<br>1 mg guanfancine</p>
<p>Rx only</p>
<p>PROMIUS PHARMA</p>
<p></p>
<p><img alt="Tenex1mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=886e050c-dd22-4f35-ac3b-243f091125c3&amp;name=Tenex1mg.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TENEX  		
					</strong><br><span class="contentTableReg">guanfacine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67857-705</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GUANFACINE HYDROCHLORIDE</strong> (GUANFACINE) </td>
<td class="formItem">GUANFACINE</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">diamond</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TENEX;1;RP</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67857-705-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:67857-705-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019032</td>
<td class="formItem">10/27/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TENEX  		
					</strong><br><span class="contentTableReg">guanfacine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67857-706</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GUANFACINE HYDROCHLORIDE</strong> (GUANFACINE) </td>
<td class="formItem">GUANFACINE</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">diamond</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TENEX;2;RP</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67857-706-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019032</td>
<td class="formItem">10/27/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Promius Pharma, LLC
							(020408265)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Puerto Rico, Inc.</td>
<td class="formItem"></td>
<td class="formItem">143814544</td>
<td class="formItem">manufacture(67857-705, 67857-706)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1b6fa629-ed24-8a9c-de2a-36bf69ea2e4d</div>
<div>Set id: 886e050c-dd22-4f35-ac3b-243f091125c3</div>
<div>Version: 7</div>
<div>Effective Time: 20130508</div>
</div>
</div> <div class="DistributorName">Promius Pharma, LLC</div></p>
</body></html>
